Cargando…

A systems biology approach to investigate the mechanism of action of trabectedin in a model of myelomonocytic leukemia

This study was designed to investigate the mode of action of trabectedin in myelomonocytic leukemia cells by applying systems biology approaches to mine gene expression profiling data and pharmacological assessment of the cellular effects. Significant enrichment was found in regulons of target genes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mannarino, L, Paracchini, L, Craparotta, I, Romano, M, Marchini, S, Gatta, R, Erba, E, Clivio, L, Romualdi, C, D’Incalci, M, Beltrame, L, Pattini, L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817395/ https://www.ncbi.nlm.nih.gov/pubmed/27958379 http://dx.doi.org/10.1038/tpj.2016.76

Ejemplares similares

Mechanism of action of trabectedin in desmoplastic small round cell tumor cells
por: Uboldi, S., et al.
Publicado: (2017)

Regional and temporal heterogeneity of epithelial ovarian cancer tumor biopsies: implications for therapeutic strategies
por: Paracchini, Lara, et al.
Publicado: (2016)

Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin
por: Bello, Ezia, et al.
Publicado: (2019)

Correction: Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin
por: Bello, Ezia, et al.
Publicado: (2020)

A Systems Biology Approach to Characterize the Regulatory Networks Leading to Trabectedin Resistance in an In Vitro Model of Myxoid Liposarcoma
por: Uboldi, Sarah, et al.
Publicado: (2012)

Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms
por: Romano, Michela, et al.
Publicado: (2017)

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
por: Belgiovine, Cristina, et al.
Publicado: (2017)

Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer
por: Paracchini, Lara, et al.
Publicado: (2022)

Editorial: Trabectedin, lurbinectedin, and other marine-derived anticancer alkaloids on solid cancer: Mechanisms of action, clinical impact, and future perspectives
por: Zambelli, Alberto, et al.
Publicado: (2023)

Trabectedin and Plitidepsin: Drugs from the Sea that Strike the Tumor Microenvironment
por: Galmarini, Carlos M., et al.
Publicado: (2014)

Liquid Biopsy in the Clinical Management of High-Grade Serous Epithelial Ovarian Cancer—Current Use and Future Opportunities
por: Paracchini, Lara, et al.
Publicado: (2021)

Trabectedin modulates the senescence-associated secretory phenotype and promotes cell death in senescent tumor cells by targeting NF-κB
por: Camorani, Simona, et al.
Publicado: (2018)

Trabectedin, a drug acting on both cancer cells and the tumour microenvironment
por: D'Incalci, M, et al.
Publicado: (2014)

Trabectedin: A drug from the sea that strikes tumor-associated macrophages
por: Allavena, Paola, et al.
Publicado: (2013)

New activities for the anti-tumor agent trabectedin: taking two birds with one stone
por: D'Incalci, Maurizio, et al.
Publicado: (2013)

Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin
por: Colmegna, B, et al.
Publicado: (2015)

Effects of the Anti-Tumor Agents Trabectedin and Lurbinectedin on Immune Cells of the Tumor Microenvironment
por: Allavena, Paola, et al.
Publicado: (2022)

Wiring miRNAs to pathways: a topological approach to integrate miRNA and mRNA expression profiles
por: Calura, Enrica, et al.
Publicado: (2014)

Tumor treating fields affect mesothelioma cell proliferation by exerting histotype-dependent cell cycle checkpoint activations and transcriptional modulations
por: Mannarino, Laura, et al.
Publicado: (2022)

Time dependence of the in vitro cytotoxicity of hexamethylmelamine and its metabolites.
por: D'Incalci, M., et al.
Publicado: (1980)

DNA Damage Response and Immune Defense
por: Nastasi, Claudia, et al.
Publicado: (2020)

Mechanism of cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cells in vitro and modulation of the drug activity by folic or folinic acid.
por: Erba, E., et al.
Publicado: (1994)

Inhibition of tumor‐associated macrophages by trabectedin improves the antitumor adaptive immunity in response to anti‐PD‐1 therapy
por: Belgiovine, Cristina, et al.
Publicado: (2021)

A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin
por: Grosso, Federica, et al.
Publicado: (2012)

Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity
por: Herzog, J., et al.
Publicado: (2016)

Sclerouveitis with exudative retinal detachment associated with chronic myelomonocytic leukemia
por: Nachbor, Kristine M., et al.
Publicado: (2022)

Mode of action of thiocoraline, a natural marine compound with anti-tumour activity
por: Erba, E, et al.
Publicado: (1999)

Transcriptional Characterization of Stage I Epithelial Ovarian Cancer: A Multicentric Study
por: Calura, Enrica, et al.
Publicado: (2019)

The Genomic Landscape of Juvenile Myelomonocytic Leukemia
por: Stieglitz, Elliot, et al.
Publicado: (2015)

5-Azacytidine in Chronic Myelomonocytic Leukemia: Case Report and Review of Literature.
por: Greco, M., et al.
Publicado: (2011)

Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents
por: Colella, G, et al.
Publicado: (1999)

Synergism between 5-fluorouracil and N-methylformamide in HT29 human colon cancer line.
por: Laudonio, N., et al.
Publicado: (1990)

Role of membrane folate-binding protein in the cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cell lines in vitro.
por: Sen, S., et al.
Publicado: (1996)

Trabectedin in Soft Tissue Sarcomas
por: Petek, Bradley J., et al.
Publicado: (2015)

Mitozolomide activity on human cancer cells in vitro.
por: Erba, E., et al.
Publicado: (1986)

Current Treatment of Juvenile Myelomonocytic Leukemia
por: Mayerhofer, Christina, et al.
Publicado: (2021)

Coexistence of Chronic Myelomonocytic Leukemia and Ulcerative Colitis With Rapid Progression to Acute Myelomonocytic Leukemia: A Case Report
por: Pelkey, Lauren J, et al.
Publicado: (2022)

Analysis of Differential miRNA Expression in Primary Tumor and Stroma of Colorectal Cancer Patients
por: Della Vittoria Scarpati, Giuseppina, et al.
Publicado: (2014)

Molecular and phenotypic diversity of CBLmutated juvenile myelomonocytic leukemia
por: Hecht, Anna, et al.
Publicado: (2020)

Deficiency of CREB and over expression of miR-183 in juvenile myelomonocytic leukemia
por: Liu, Y L, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_5p7l7rkmfbl4p6na3t753873k2